Literature DB >> 7926462

Point mutation of K-ras gene codon 12 in biliary tract tumors.

M Watanabe1, M Asaka, J Tanaka, M Kurosawa, M Kasai, T Miyazaki.   

Abstract

BACKGROUND/AIMS: Point mutations of the K-ras gene have been reported in a wide variety of human tumors. However, there might be conflicting data about its presence or incidence in biliary tract tumors. The aim of this study is to elucidate the presence and types of point mutation in biliary tract tumors, including gallbladder carcinoma and adenoma, extrahepatic bile duct carcinoma, and ampullary carcinoma.
METHODS: Mutation bands detected in modified two-step polymerase chain reaction were eluted from agarose gel and analyzed by dideoxy sequencing method.
RESULTS: Of 20 biliary tract tumors showing a mutation band, G to A single base substitutions were confirmed in 15 cases as the most frequent changes, which were divided into changes for aspartic acid (GAT) and (14) serine (AGT) (1). Changes for valine (GTT) were found in two cases. In extrahepatic bile duct carcinoma, duplicate mutations (GA/TT) were found in two cases and triplicate mutation (A/GA/TT) in one case. The adenoma portion of one "cancer in adenoma" case of gallbladder showed the single base transition (GAT) in the second position, same as in the carcinoma portion.
CONCLUSIONS: Most of the biliary tract tumors comprised point mutation in K-ras gene codon 12, and G to A transition was the most frequent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926462     DOI: 10.1016/0016-5085(94)90240-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  22 in total

1.  Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients.

Authors:  R H Hruban; P D Sturm; R J Slebos; R E Wilentz; A R Musler; C J Yeo; T A Sohn; M L van Velthuysen; G J Offerhaus
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Frequent activation of mitogen-activated protein kinase relative to Akt in extrahepatic biliary tract cancer.

Authors:  Hiroshige Hori; Tetsuo Ajiki; Yoshiyasu Mita; Hideki Horiuchi; Kenro Hirata; Taku Matsumoto; Haruki Morimoto; Tsunenori Fujita; Yonson Ku; Yoshikazu Kuroda
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

Review 3.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 4.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

5.  Using 2-step PCR and restriction endonuclease digestion to detect K-ras mutation in paraffin-embedded tissues: is it reliable?

Authors:  W C Su; N H Chow; C H Huang; H S Liu
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

6.  Pancreaticobiliary maljunction: pathophysiological and clinical aspects and the impact on biliary carcinogenesis.

Authors:  Yoshiro Matsumoto; Hideki Fujii; Jun Itakura; Masanori Matsuda; Yang Yang; Bunsei Nobukawa; Kohichi Suda
Journal:  Langenbecks Arch Surg       Date:  2003-04-09       Impact factor: 3.445

7.  Genetic alterations and growth pattern in biliary duct carcinomas: loss of heterozygosity at chromosome 5q bears a close relation with polypoid growth.

Authors:  E Hidaka; A Yanagisawa; M Seki; T Setoguchi; Y Kato
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

8.  Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases.

Authors:  Michelle D Reid; Serdar Balci; Nobuyuki Ohike; Yue Xue; Grace E Kim; Takuma Tajiri; Bahar Memis; Ipek Coban; Anil Dolgun; Alyssa M Krasinskas; Olca Basturk; David A Kooby; Juan M Sarmiento; Shishir K Maithel; Bassel F El-Rayes; Volkan Adsay
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

9.  Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders.

Authors:  W C Su; S C Shiesh; H S Liu; C Y Chen; N H Chow; X Z Lin
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

10.  Is there a role for estrogen and progesterone receptors in gall bladder cancer?

Authors:  P J Shukla; S G Barreto; P Gupta; R Neve; M Ramadwar; K Deodhar; S Mehta; S V Shrikhande; K M Mohandas
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.